The Bounce-back Effect: What Happens After Cessation of Low-dose Semaglutide in People With HIV
Short-term, low-dose, semaglutide was associated with cardiometabolic benefit in PWH, but rapid weight regain and some loss of cardiometabolic benefit occurred after stopping semaglutide, similar to the general population. Further study of higher dose semaglutide and strategies to maintain benefits following initial therapy are needed in PWH. ClinicalTrials.gov: NCT04216589.
Authors
- Sonya L. Heath (ORCID: https://orcid.org/0000-0002-3826-0954)
- Kristine Mace Erlandson (ORCID: https://orcid.org/0000-0003-0808-6729)
- Carl J. Fichtenbaum (ORCID: https://orcid.org/0000-0002-6778-7253)
- Douglas Kitch
- Amy Kantor
- Jordan E. Lake (ORCID: https://orcid.org/0000-0002-0640-5514)
- Fred R. Sattler (ORCID: https://orcid.org/0000-0002-1986-6803)
- Todd T. Brown (ORCID: https://orcid.org/0000-0001-8599-278X)
- Pablo F. Belaunzarán-Zamudio (ORCID: https://orcid.org/0000-0003-4775-4734)
Institutions
- University of Southern California (US)
- Harvard University (US)
- Johns Hopkins University (US)
- Johns Hopkins Medicine (US)
- University of Alabama at Birmingham (US)
- National Institute of Allergy and Infectious Diseases (US)
- The University of Texas Health Science Center (US)
- University of Colorado Anschutz Medical Campus (US)
- University of Cincinnati (US)
- The University of Texas Health Science Center at Houston (US)
Publication Details
- Journal
- Clinical Infectious Diseases
- Published
- 2025-11-25
- DOI
- https://doi.org/10.1093/cid/ciaf652
- Primary Topic
- HIV-related health complications and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00